Abstracts tagged "SLE and gene therapy"

Abstract Number: 2991 • 2016 ACR/ARHP Annual Meeting
A Molecular Signature Based on IFN Gene Signature and Serology Defines Two Populations of Patients with Different Baseline Disease Activity in a Large Multinational Phase 3 SLE Trial Population
Michelle Petri¹, Kenneth C. Kalunian², Murray Urowitz³, David A. Isenberg⁴, Richard Furie⁵, MaryAnn Morgan-Cox⁶, Maria Silk⁷, Ernst R. Dow⁸, Richard Higgs⁷, Steven Watts⁷ and Matthew D Linnik⁹, ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ⁵North Shore University Hospital, Great Neck, NY, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly, Indianapolis, IN, ⁸Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, ⁹Immunology, Lilly Biotechnology Center, San Diego, CA
Background/Purpose: Registration trials for SLE therapeutics require large numbers of patients with active disease, which in turn necessitates the trials be multinational with many participating…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].